THE EXPRESSION OF PROTOONCOGENES IN HUMAN GASTRIC CANCER CELL LINES AND PRIMARY GASTRIC CANCERS DEFINED BY IN SITU HYBRIDIZATION

The expression of several protooncogenes was detected in three different differentiated gastric cancer cell lines (MKN28, MKN45, SGC7901) and 5 specimens from 5 human primary gastric cancers at cellular level by in situ hybridization. The data indicated that there were high levels of c-Ha-ras expression in both cell lines and tumor tissues as compared with control samples. But the transcripts of c-myc and c-erbB were rather low. The results suggested that Ha-ras be involved in or associated with the gastric cancer. There were another two interesting findings: (1) The levels of c-Ha-ras was different among the individual cancer cells within a single gastric cnacer. (2) Some inflammatory cells in the tumor tissuse and normal tissues adjacent to the cancer displayed high level of c-Ha-ras expression. Those two phenomena are worthwhile for further study.

DETECTING EXPRESSION OF MRP-1/CD9 mRNA IN LUNG CANCERS USING TISSUE MICROARRAYS AND FLUORESCENCE IN SITU HYBRIDIZATION METHODS

Objective： The aim of this study was to investigate the MRP-1/CD9mRNA expression in lung cancer and normal lung tissues and the relationship between its expression and pathologic grades, clinical stages, metastasis and prognosis. Methods： To observe MRP-1/C9mRNA expression, tissue microarray （TMA） containing 54 lung cancers and 10 normal lung tissues was prepared and Fluorescence in situ hybridization was used. Results： The positive rate of MRP-1/CD9 expression was 48.1% in lung cancer, lower than that of normal lung tissues. The statistical difference was significant （P〈0.05）. Its protein expression had no relationship with the patients＇ ages, sex and the macroscopic type of tumor, but had relationships with the histological type, clinical stage, differentiated degree and metastasis. The expression in non-small cell lung cancer （NSCLC） was higher than that in small cell lung cancer （SCLC）; in well-moderately differentiated group was higher than that in poorly differentiated group; Earlier period group （I＋II） was higher than in later period group （Ⅲ＋Ⅳ）; and in group without lymphoid metastasis was higher than in patients with lymphoid metastasis. Conclusion： The progression of the lung cancer maybe related with the descended MRP-1/Cd9 expression, which may be useful in evaluating the prognosis of cancer patients.

Predictive biomarker and clinicopathological characteristics analysis for recurrence of early gastric cancer

Objective: The aim of this study was to identify the correlation between the clinicopathological characteristics and recurrence in early gastric cancer (EGC), what's more, we attempt to look for a predictive biomarker to predict and treat for re-currence of EGC. Methods: This study retrospectively analyzed 178 early gastric cancer patients who had the complete post-operative and follow-up medical records in the First Affiliated Hospital of Yangtze University (China) between January 1995 to December 2005. All of them were followed-up to December 2009 regularly. Computer tomography (CT), endoscopy, and single photon emission computed tomography (SPET-CT) were used to diagnose for recurrence of EGC. Immunohistochem-istry (IHC) and fluorescence in situ hybridization (FISH) were used for the detection of cerbB2. Chi-square test was applied to this study for statistics analysis. Results: Fourteen patients had recurrence. Eighteen patients were cerbB2-positive, including twelve recurrence patients and six norecurrence patients. Sex, tumor depth, and lymph node metastasis were related to the recurrence of EGC. Also, cerbB2-positive patients had the higher recurrence rate compared to the cerbB2-negative patients. Conclusion: Recurrence of EGC after curative resection can be predicted by using some clinicopathological characteristics. CerbB2 can be used as a predictive biomarker for recurrence of EGC.

Correlations of β-catenin,Ki67 and Her-2/neu with gastric cancer

Objective:To study the clinical pathologic characteristics ofβ-catenin,Ki67 and Her-2/neu in gastric cancer and the correlation ofβ-catenin and Ki67 to the protein expression and gene conditions of Her-2/Neu.Methods:The protein expression ofβ-catenin,Ki67 and Her-2/Neu was detected by immunohistochemistry in 101 cases of gastric cancer and the gene conditions of Her-2/Neu by fluorescence in situ hybridization(FISH).Results:The protein expression ofβ-catenin,Ki67 and Her-2/Neu had close relationship with the clinical pathologic characteristics of gastric cancer.Theβ-catenin and Ki67 had obvious correlation to the differentiation,infiltration and lymphatic metastasis of the gastric cancer(P<0.05).The Ki67 had close relationship with the tumor-node-metastasis staging staging of gastric cancer(P<0.05).Her-2/Neu had close relationship with the differentiation and tumor-node-metastasis staging of gastric cancer(P<0.05)but had no relationship with the infiltration and lymphatic metastasis of the gastric cancer(P<0.05).The protein expression of Ki67 had significantly positive correlation to the protein expression and gene amplification conditions of Her-2/Neu(r=0.567,P<0.05 for protein;r=0.304,P<0.05 for gene).Conclusions:Combined detection ofβ-catenin,Ki67 and Her-2/Neu can be used as a reliable method to help the observation of biological behavior,diagnosis and prognosis of gastric cancer,and Ki67 can be used to serve the preliminary screening of Her-2/Neu gene state.

A COMPARISON OF THE PROTOONCOGENES BETWEEN THE HUMAN GASTRIC CANCEROUS AND NORMAL MUCOSAL TISSUES

The allelic distribution of EcoRI and BamHI fragments of ras family genes between the human primary gastric cancer tissues and the corresponding adjacent normal tissues did not show any differences. Three genotypes of BamHI restriction fragment length polymorphism of c-H-ras were revealed. No significant differences in the RFLPs were observed between normal individuals and gastric cancer patients. Four protooncogenes, c-H-ras, N-ras, c-myc and c-fos, were found to be transcriptionally active in the gastric cancer tissues in some cases examined. The comparison of the expression of these oncogenes between the malignant tissues and the corresponding normal tissues showed differential patterns. The expression of c-H-ras at cellular level was detected by in situ hybridization. The enhanced expression of c-H-ras in the gastric cancer cells was demonstrated, but the degree of the expression among the cancer cells was shown to be heterogeneous. In addition, the enhanced expression of c-H-ras was seen in the inflammatory cells.

Expression of heat shock protein 90 β in human gastric cancer tissue and SGC7901/VCR of MDR type gastric cancer cell line

Objective To examine the expression of heat shock protein (HSP) 90 β in human gastric cancer tissue and SGC7901/VCR of MDR type gastric cancer cell line Methods Immunohistochemical staining and in situ hybridization methods Results Heat shock protein 90 β was mainly located in the cell cytoplasma and weakly expressed in non cancerous gastric mucosa The expression rates of HSP90 β in normal gastric mucosa, gastritis and para cancer tissues were 11 76%, 13 04% and 11 42% respectively,and there were no significant differences between them ( P >0 05) The expression of HSP90 β was increased in gastric cancer The positive rate of HSP90 β in gastric cancer tissue was 30 00%, and was higher than non cancerous gastric mucosa ( P <0 05) The expression rates of HSP90 β in well differentiated, moderately differentiated, poorly differentiated gastric cancer and mucinous carcinoma were 15 38%, 31 25%, 33 33%, and 42 85% respectively The expression of HSP90 β in SGC7901/VCR of MDR type gastric cell line was higher than in its parental cell line SGC7901 In situ hybridization showed that the positive signal of HSP90 β was mainly located in the cell cytoplasma Conclusions The expression of HSP90 β was higher in gastric cancer tissue than in non cancerous gastric mucosa In gastric cancer tissue, the expression of HSP90 β was greater in poorly differentiated cancer tissue, and in SGC7901/VCR of MDR type gastric cancer cell line the expression of HSP90?β was higher than that in its parental cell line SGC7901

Expression of VEGFR2 and NRP-1 in non-small cell lung cancer and their clinical significance

Objective： Vascular-targeted therapy is gradually becoming more appealing for patients with lung cancer. It is unclear whether vascular endothelial growth factor receptor 2（VEGFR2） and neuropilin-1（NRP-1） can be biomarkers for clinical treatment. We aimed to investigate the expression levels of VEGFR2 and NRP-1 in human non-small cell lung cancer（NSCLC） and their clinical significance by observing patient prognosis. Methods： VEGFR2 and NRP-1 were assessed by immunohistochemistry（IHC） in 40 patients with NSCLC and in 10 patients with benign lesions of lung; kinase insert domain receptor（KDR） and NRP-1 copy number gain（CNG） was assessed by fluorescence in situ hybridization（FISH）. The distributions of overall survival（OS） and progression-free survival（PFS） were estimated using the Kaplan-Meier method and compared between groups by log-rank test.Results： Rates of positive immunostaining for VEGFR2 and NRP-1 were 58% and 55%, respectively. KDR and NRP-1 CNG（＋） were detected in 32.5% and 30% of tumors, respectively. Levels of both VEGFR2 and NRP-1 in lung tumors were significantly different than in the control tissue（χ2=11.22, P=0.001; χ2=9.82, P=0.001, respectively）; similar results were obtained using CNGs（χ2=4.39, P=0.036; χ2=3.95, P=0.046, respectively）. Statistically significant correlations were observed with histological grade, clinical TNM stage and the lymph node status（P〈0.05）, but not age, gender or pathology type（P〉0.05）. VEGFR2 showed a strong correlation with NRP-1（Rs=0.68, P=0.00）; similar results were observed with KDR and NRP-1 CNG（Rs=0.32, P=0.04）. Significant differences in OS and PFS were observed between the groups with higher VEGFR2 and NRP-1 and those with lower expression（P〈0.05）. Conclusions： According to these data, VEGFR2 and NRP-1 are highly expressed in NSCLC. We can conclude that they play a key role in NSCLC occurrence, development and metastasis and are associated with patient prognosis（P〈0.05 for OS and PFS）. This information will be beneficial for clinical antiangiogenic treatment in NSCLC.

miR-124在胃癌中的表达及临床意义

背景与目的:miR-124在多种肿瘤中发挥抑癌基因样功能,如肺癌、前列腺癌、膀胱癌和乳腺癌,但是其在胃癌中的表达及临床意义尚不清楚。该研究旨在研究miR-124在正常胃黏膜上皮细胞与不同胃癌细胞及胃癌组织及正常胃黏膜组织中的表达,分析其表达与胃癌患者性别、年龄、组织学分级、T分期、TNM分期、淋巴结转移及预后之间的相关性。方法:采用实时荧光定量聚合酶链反应(real-time fluorescent quantitative polymerase chain-reaction,RTFQ-PCR)检测miR-124在人胃黏膜上皮细胞及胃癌细胞中的表达,采用原位杂交法检测miR-124在胃癌及癌旁正常组织中的表达。结果:RTFQ-PCR结果显示,miR-124在胃癌MKN-74、MKN-28、MKN-45、MGC-803、SGC-7901及AGS细胞中的表达均低于GES-1细胞;原位杂交实验结果显示,miR-124在正常胃黏膜中呈强阳性表达,在胃腺癌组织中表达下降、局灶阳性或缺失;统计分析显示,miR-124与胃腺癌患者组织学分级、TNM分期及淋巴结转移密切相关,与患者的年龄、性别及肿瘤大小无关;Kaplan-Meier生存曲线统计分析显示,miR-124低表达患者的总生存时间和无病生存时间显明低于miR-124高表达患者;多因素分析结果提示,miR-124表达下调是影响患者生存的独立预后因素。结论:miR-124在胃癌细胞及组织中表达下调,并且与患者的组织学分级、TNM分期、淋巴结转移及预后密切相关。

Y-box结合蛋白-1在胃癌组织中的表达及意义

目的研究Y-box结合蛋白-1(YB-1)在胃癌的不同发展阶段中的表达及其意义。方法采用免疫组织化学和原位杂交方法检测正常胃组织、肠化生组织、早期胃癌和进展期胃癌组织中YB-1蛋白和mRNA的表达变化。结果在正常胃组织中YB-1蛋白和mRNA无表达;在肠化生组织中可见YB-1阳性染色于胃黏膜上皮细胞中,但表达较弱;在早期胃癌中YB-1表达于全层胃黏膜上皮细胞中,染色较肠化生组织重,而在进展期胃癌中其表达较在早期胃癌中下降。结论 YB-1的升高可能在胃癌的早期发生和发展中起作用。

胃癌组织EB病毒感染与miR-101 EZH2 COX-2表达关系的研究

目的:探讨甘肃省武威地区胃癌患者EB病毒(Epstein-Barr virus,EBV)感染状况及miR-101、EZH2、COX-2在EBV相关胃癌发生发展中的作用。方法:应用组织芯片、原位杂交和免疫组织化学技术检测120例胃癌组织及相应癌旁组织中EBV小RNA(EBER)、miR-101、EZH2、COX-2的表达情况。结果:120例胃癌组织EBV阳性率为10.0%,EBV相关胃癌有较少的淋巴结转移,好发于贲门、胃体(P<0.05)。miR-101、EZH2、COX-2在120例胃癌组织和相应癌旁组织的阳性率差异有统计学意义(P<0.05)。12例EBV阳性胃癌组织miR-101、EZH2、COX-2和108例EBV阴性胃癌组织3个分子的表达率差异有统计学意义(P<0.05)。胃癌组织EBV感染和miR-101表达呈正相关,EBV相关胃癌组织miR-101表达和淋巴结转移、COX-2、EZH2表达均呈负相关(P<0.05)。结论:EB病毒感染与武威地区胃癌的发生有一定关系;EBV相关胃癌和EBV阴性胃癌在淋巴结转移和发生部位的差异有统计学意义;miR-101、EZH2、COX-2与EB病毒相关胃癌的发展有一定关系。

乳腺癌易感基因1和切除修复交叉互补基因1 mRNA在乳腺癌中的表达及意义

目的研究乳腺癌易感基因1(BRCA1)和切除修复交叉互补基因1(ERCC1)在乳腺癌发生、发展中的作用及临床意义。方法采用原位杂交技术(ISH)检测BRCA1和ERCC1 m RNA在乳腺癌癌前病变和乳腺癌组织芯片中的表达,以及与乳腺癌临床病理因素的关系。结果 1BRCA1和ERCC1 m RNA在乳腺癌旁正常组织、乳腺癌癌前病变及乳腺癌组织中的阳性表达率呈递减趋势,差异有统计学意义(P<0.05)。2BRCA1和ERCC1 m RNA在乳腺癌的表达差异显著并具有相关性(P<0.01)。3BRCA1 m RNA的阳性表达与乳腺癌组织学分级、肿瘤大小呈负相关(P<0.05),与发病年龄、临床分期和淋巴结转移无关(P>0.05),ERCC1m RNA的表达与肿瘤大小和淋巴结转移相关(P<0.05),与患者发病年龄、组织学分级及临床分期无关(P>0.05)。结论 BRCAl与ERCC1 m RNA表达的减少可能与乳腺癌的发生发展有关,两基因的联合检测有利于乳腺癌的早期诊断与治疗。

乳腺癌中c-erbB-2与HIF-1基因表达相关性研究

目的探讨c-erbB-2与HIF 1基因过表达在乳腺癌进程中的内在相关性,寻找检测癌浸润转移的联合分子指标。方法乳腺癌组织芯片中200例样品经原位杂交检测c-erbB-2和HIF-1 mRNA表达,87例样本经荧光原位杂交检测c-erbB-2基因扩增。结果①185例乳腺癌样本中c-erbB-2和HIF 1基因有不同程度的共表达,浸润型的非特殊导管癌I级中c-erbB-2与HIF-1的表达2级以上的样本比率都超过70%。非特殊导管癌Ⅰ、Ⅱ级中c-erbB-2表达的样本比率高于HIF-1。c-erbB-2和HIF 1基因在非特殊导管癌Ⅰ、Ⅱ级中两者表达存在显著差异(P=0.003,P=0.036),小叶癌中两者表达无显著差异(P=0.607)。②浸润型的非特殊性导管癌Ⅰ级中c-erbB-2基因扩增与表达存在显著差异(P=0.046),非特殊性导管癌Ⅱ级与小叶癌中差异不显著(P=0.496m,P=0.878)。结论在乳腺癌浸润转移程度高时,c-erbB-2与HIF-1 mRNA的过表达一致,c-erbB-2扩增与其过表达一致,两者可成为乳腺癌浸润转移的联合分子指标。

Relationships between mucinous gastric carcinoma, MUC2 expression and survival

AIM:To investigate the expression of the four secreted gel-forming mucins(MUC2,MUCSAC,MUCSB and MUC6)in a series of gastric carcinomas,classified according Laurén's,Mulligan's,WHO and Goseki's classifications,with special attention to all the different components(major and minor)present in tumors and to follow up clinical data.METHODS:Expression of MUC2,MUC5AC,MUC5B and MUC6 was investigated using immunohistochemistry and in situ hybridization.RESULTS:Expression of secreted gel-forming mucins in gastric carcinoma was particularly complex,each mucin being not restricted to any histopathological type even considering all components(major and minor)present in a given tumor.There was a worst survival in patients with a higher content of mucus(GosekiⅡorⅣ)and high positive MUC2 expression.CONCLUSION:Complexity of mucin gene expression patterns in gastric cancer may reflect a precise state of differentiation at the cell level not recognized in used morphologic classification systems.High expression of MUC2 was nevertheless associated with mucinous subtype of the WHO classification and with groupⅡof Goseki's classification identified by the major component of a particular tumor.The quantity and quality of mucus were related to survival.

CAC1基因在人胃癌细胞和组织中的表达

目的了解CAC1(CDK-associated cullin1)基因在胃癌细胞和组织中的表达情况。方法选取人胃黏膜细胞系GES-1和人胃癌细胞系AGS、MGC803和BGC823,采用实时定量PCR法检测CAC1基因在胃癌细胞系和胃黏膜细胞系中的表达水平,比较其在胃黏膜细胞和胃癌细胞中的表达水平;选取35例胃腺癌组织及相应正常组织标本,采用原位杂交法检测CAC1基因在胃癌组织和癌周围正常组织中的表达情况,分析CAC1在胃癌组织中的表达水平与临床因素的相关性。结果胃癌细胞系和胃黏膜细胞系GES-1中均检测出CAC1 mRNA的表达,胃癌细胞系(AGS、MGC803、BGC823)中CAC1 mRNA水平明显高于胃黏膜细胞系GES-1(1.000 0±0.000 0,0.950 7±0.017 6,0.434 0±0.041 4 vs 0.201 7±0.008 2,P<0.05);原位杂交结果显示,CAC1在胃癌组织中表达水平高于癌周围正常组织(57.14%vs 25.71%,P<0.05),主要表达于肿瘤细胞的胞质。而且,其在癌组织中的阳性表达率随着临床分期增高而增高(Ⅰ-Ⅱ期表达率37.50%,Ⅲ-Ⅳ期表达率73.68%,P<0.05),与患者年龄、细胞分化程度、淋巴结转移等因素无关(P>0.05)。结论 CAC1在胃癌细胞系和胃癌组织中的表达水平明显高于胃黏膜细胞系和癌周围正常组织,其在癌组织中的阳性表达率与临床分期有关。

miR-4286与AEG-1在非小细胞肺癌组织中的表达及临床意义

目的探讨miR-4286、星形胶质细胞上调基因-1 (AEG-1)在非小细胞肺癌(NSCLC)组织中的表达及与NSCLC临床病理特征的关系。方法分别采用原位杂交方法和免疫组织化学染色检测组织芯片中140例NSCLC癌组织及癌旁正常组织中miR-4286、AEG-1的表达,并分析两者表达水平与NSCLC临床病理特征的关系。结果 NSCLC癌组织中miR-4286高表达率为62.14%,高于癌旁正常组织的4.29%,差异有统计学意义(P<0.01);NSCLC癌组织中AEG-1高表达率为55.71%,高于癌旁正常组织的7.86%,差异有统计学意义(P<0.01)。miR-4286高表达与患者肿瘤直径大小、肿瘤TNM分期和淋巴结转移均有关(均P<0.05),AEG-1高表达与患者肿瘤TNM分期和淋巴结转移均有关(均P<0.05)。Spearman等级相关分析显示NSCLC癌组织中miR-4286的表达与AEG-1的表达呈正相关(r=0.223,P=0.008)。结论 NSCLC癌组织中miR-4286与AEG-1均高表达,miR-4286与AEG-1表达水平与TMN分期和淋巴结转移均有关,提示miR-4286和AEG-1可能参与NSCLC的发生、发展与转移。

1HAI-1,ST14在非小细胞肺癌中的表达及意义

目的检测HAI-1mRNA和ST14mRNA在非小细胞肺癌组织与正常肺组织中的表达并分析其与临床病理的关系。方法应用原位杂交技术,积分光密度半定量,检测ST14mRNA和HAI-1mRNA在非小细胞肺癌及相应的正常肺组织中的表达。结果HAI-1mRNA和ST14mRNA在非小细胞肺癌组织中表达低于正常肺组织(P<0.05),在高分化癌组织表达高于低分化组织(P<0.05),在无淋巴结转移组表达高于有淋巴结转移组(P<0.05),与年龄,性别,癌组织类型无关(P>0.05)。结论在肿瘤进程中,HAI-1mRNA和ST14mRNA转录受抑制,两基因在肺癌中可能表现为抑癌基因。HAI-1mRNA和ST14mRNA与肺癌的分化程度有关,可能参与促进细胞分化成熟,并且其表达降低可能促进肿瘤的转移。

胃癌组织中KiSS-1 mRNA及蛋白的表达

目的探讨胃癌组织中KiSS-1 mRNA及蛋白的表达情况。方法分别采用原位杂交方法和免疫组织化学SP法对40例胃癌组织、22例癌旁不典型增生组织及40例正常胃黏膜组织进行KiSS-1 mRNA和蛋白的检测。结果胃癌组织、癌旁不典型增生组织及正常胃黏膜组织中KiSS-1 mRNA的阳性表达率分别为57.5%(23/40)、77.3%(17/22)、97.5%(39/40),依次升高(X2=18.323,P<0.01);KiSS-1蛋白的阳性表达率分别为52.5%(21/40)、81.8%(18/22)、95.0%(38/40),依次增高(X2=20.131,P<0.01);胃癌组织中KiSS-1 mRNA及蛋白表达与胃癌分化程度无关(P>0.05),与浸润深度、淋巴结转移有关(P<0.05);胃癌组织中KiSS-1 mRNA与蛋白的表达呈正相关(rs=0.702,P<0.05)。结论 KiSS-1表达缺失与胃癌的发生、转移有关;KiSS-1有望成为胃癌早期诊断和判断预后的辅助指标。

多肿瘤抑制基因MTS_1 mRNA和蛋白在胃癌及癌前病变中的表达及意义

目的 :探讨多肿瘤抑制基因 (MTS1)在胃癌发生、发展中的意义和临床应用价值。方法 :应用原位分子杂交技术、免疫组织化学技术分别检测 2 10例标本中MTS1基因mRNA及其蛋白的表达规律。结果 :正常胃粘膜、轻、中度异型增生及小肠型肠化间差异无显著性 (P >0 .0 5 ) ,但与重度异型增生、结肠型肠化及胃癌组织间差异有显著性 (P <0 .0 1) ,而后三者相互间差异则无显著性 (P >0 .0 5 )。正常胃粘膜与轻、中度异型增生之间MTS1蛋白表达的阳性率及强阳性率差异均无显著性 (P >0 .0 5 ) ;正常胃粘膜与重度异型增生之间MTS1蛋白阳性率差异无显著性 (P >0 .0 5 ) ,而强阳性率间差异则有显著性 (P <0 .0 1)。正常胃粘膜与两型肠化及胃癌组织间的阳性率、强阳性率差异均有显著性 (P <0 .0 5 ,P <0 .0 1) ,重度异型增生、两型肠化与胃癌组织间的阳性及强阳性差异均无显著性 (P >0 .0 5 ) ;MTS1蛋白阴性表达患者五年生存率与阳性表达者差异无显著性 (P >0 .0 5 ) ,而两者与强阳性表达者的差异则有显著性 (P <0 .0 1)。结论 :MTS1基因变异在胃癌的发生、发展中具有重要意义。MTS1基因mR NA及其蛋白表达的检测有助于胃癌的早期诊断和治疗 ;

RPS12基因表达与胃癌进展及淋巴结转移的研究

目的探讨核糖体蛋白S12(RPS12)基因表达与胃癌进展及淋巴结转移的关系。方法采用原位杂交方法检测39例进展期胃癌组织、17例正常胃黏膜中RPS12mRNA表达。结果胃癌中RPS12mRNA表达阳性表达率(87.2%)显著高于正常胃黏膜(17.6%),P<0.01;淋巴结转移阳性的胃癌中RPS12mRNA表达阳性率(96.2%)显著高于淋巴结转移阴性者(69.2%),P<0.05。结论RPS12基因高表达与胃癌进展及淋巴结转移有关。

CCN家族成员CYR61 NOV mRNA在胃癌中的表达及意义

目的:探讨CCN家族成员CYR61(cysteine-rich61)mRNA和NOV(nephroblastoma overexpressed genes)mRNA在胃癌中的表达及其与胃癌发生、发展及预后的关系。方法:合成地高辛标记的cRNA探针,在组织芯片上进行原位杂交,检测100 例胃癌组织和25 例正常胃粘膜组织中CYR61 mRNA 和NOV mRNA 的表达情况。结果:CYR61 mRNA在正常胃粘膜和胃癌组织中的表达率分别为4.0%(1/25)和37.0%(37/100),两者之间有显著性差异(P=0.001);NOV mRNA在正常胃粘膜和胃癌组织中的表达率分别为64.0%(16/25)和52.0%(52/100),两者差异不显著(P=0.244)。CYR61 mRNA在胃癌中的表达增高与肿瘤大小(r=0.318,P=0.001)、浸润深度(r=0.235,P=0.014)、TNM分期(r=0.331,P=0.007)、淋巴结转移(r=0.285,P=0.004)和脉管侵犯(r=0.292,P=0.004)呈正相关;与胃癌的分化程度无关(r=0.037,P=0.709);CYR61 mRNA阳性表达的胃癌患者5年生存率低于阴性表达者(P=0.000)。相反,NOV mRNA的表达减低与胃癌的浸润深度(r=-0.262,P=0.009)和分化程度(r=-0.244,P=0.015)呈负相关;与肿瘤大小(r=-0.050,P=0.619)、TNM 分期(r=-0.080,P=0.317)、淋巴结转移(r=-0.120,P=0.232)和脉管侵犯(r=-0.062,P=0.537)无关;且NOV mRNA表达情况与胃癌患者的生存时间无明显相关性(P=0.052)。结论:在胃癌发生、发展过程中,CYR61可能发挥了促进作用,而NOV可能具有抑制因子的作用。